Esmolol
Esmolol is a very short-acting intravenous beta blocker used in hospital settings for short-term control of fast heart rhythms (including atrial fibrillation and atrial flutter) and for fast heart rate and high blood pressure around surgery.
🧬 Where this information comes from
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 24 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Esmolol is a very short-acting beta blocker, a hospital standby since the early 1980s and available generically. It blocks beta-1 receptors in heart muscle to slow a racing heart in atrial fibrillation, atrial flutter and other fast rhythms, and to calm fast heart rate and high blood pressure around surgery. It runs as a drip into a vein under close monitoring and wears off within minutes of stopping, so it is usually well tolerated, though low blood pressure, sometimes with dizziness, is the side effect most often seen. Speak up right away if you feel faint or lightheaded, since blood pressure and heart rate can drop too far.
Clinical pearls
- If you have asthma or another reactive airway disease, tell the team, since esmolol can trigger wheezing.
- Report pain, swelling or blistering where the drip goes in, because esmolol can irritate or damage the vein and skin.
- With diabetes, esmolol can hide the racing pulse of low blood sugar and boost the effect of insulin.
- Make sure the team knows if you take digoxin, clonidine or guanfacine, since each one interacts with esmolol.
Patient Information Guide A plain-language walkthrough of Esmolol, written from its FDA label.
What Esmolol Is Used For
▾
Esmolol is used short term for fast heart rhythms and for fast heart rate and high blood pressure around surgery.
- Rapid control of ventricular rate in atrial fibrillation or atrial flutter during or after surgery, or in other emergencies
- Noncompensatory sinus tachycardia when the doctor decides the fast rate needs treatment
- Fast heart rate and high blood pressure during intubation, surgery, emergence from anesthesia and the recovery period
- Brevibloc injection and the other intravenous esmolol injection products are labeled for these uses
- Not recommended to prevent these events
How Esmolol Works
▾
Esmolol is a cardioselective beta blocker. It mainly blocks beta-1 receptors in heart muscle, which slows the heart rate. It acts quickly and has a very short duration of action. At higher doses it can begin to block beta-2 receptors in the airways and blood vessels.
Esmolol Dosage
▾
Esmolol is given only into a vein by a healthcare team, usually as a continuous infusion.
- A starting loading dose may be given first
- The rate is adjusted step by step, based on heart rate or blood pressure checked at least every 4 minutes
- It is meant for short-term use
Dosing details from the FDA-approved label
From the Esmolol prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia
- Optional loading dose: 500 mcg per kg infused over one minute, then 50 mcg per kg per minute for the next 4 minutes
- Step-wise dosing: optional loading dose if necessary, then 100 mcg per kg per min for 4 min, then 150 mcg per kg per min for 4 min, then if necessary increase to 200 mcg per kg per min
- Effective maintenance dose is 50 to 200 mcg per kg per mi
- Maximum: 200 mcg per kg per minute
- Titrate using ventricular rate or blood pressure at ≥ 4 minute intervals; maintenance infusions may be continued for up to 48 hours
- Intraoperative and postoperative tachycardia and hypertension - immediate control
- 1 mg per kg as a bolus dose over 30 seconds followed by an infusion of 150 mcg per kg per min if necessary
- Adjust the infusion rate as required to maintain desired heart rate and blood pressure
- Maximum: 200 mcg per kg per min for tachycardia; for hypertension, higher maintenance dosages (250 to 300 mcg per kg per min) may be required; safety of doses above 300 mcg per kg per minute has not been studied
- Intraoperative and postoperative tachycardia and hypertension - gradual control
- 500 mcg per kg as a bolus dose over 1 minute followed by a maintenance infusion of 50 mcg per kg per min for 4 minutes
- Depending on the response obtained, continue dosing as outlined for supraventricular tachycardia
- Maximum: 200 mcg per kg per min for tachycardia; for hypertension, higher maintenance dosages (250 to 300 mcg per kg per min) may be required; safety of doses above 300 mcg per kg per minute has not been studied
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Administer intravenously ( 2.1 , 2.2 ) • Titrate using ventricular rate or blood pressure at ≥ 4 minute intervals ( 2.1 , 2.2 ) • Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia ( 2.1 ) • Optional loading dose: 500 mcg per kg infused over one minute • Then 50 mcg per kg per minute for the next 4 minutes • Adjust dose as needed to a maximum of 200 mcg per kg per minute • Additional loading doses may be administered • Perioperative tachycardia and hypertension ( 2.2 ) • Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control) • Then 50 mcg per kg per minute for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per minute ( 2.2 ) 2.1 Dosing for the Treatment of Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride is administered by continuous intravenous infusion with or without a loading dose. Additional loading doses and/or titration of the maintenance infusion (step-wise dosing) may be necessary based on desired ventricular response. Table 1: Step-Wise Dosing Step Action 1 Optional loading dose (500 mcg per kg over 1 minute), then 50 mcg per kg per min for 4 min 2 Optional loading dose if necessary, then 100 mcg per kg per min for 4 min 3 Optional loading dose if necessary, then 150 mcg per kg per min for 4 min 4 If necessary increase dose to 200 mcg per kg per min In the absence of loading doses, continuous infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes. The effective maintenance dose for continuous and step-wise dosing is 50 to 200 mcg per kg per minute, although doses as low as 25 mcg per kg per minute have been adequate. Dosages greater than 200 mcg per kg per minute provide little added heart-rate lowering effect, and the rate of adverse reactions increases. Maintenance infusions may be continued for up to 48 hours. 2.2 Intraoperative and Postoperative Tachycardia and Hypertension In this setting it is not always advisable to slowly titrate to a therapeutic effect. Therefore two dosing options are presented: immediate control and gradual control.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Esmolol Side Effects
▾
Most side effects are mild and short-lived.
Common side effects
- Low blood pressure, with or without symptoms
- Sweating
- Dizziness
- Irritation or inflammation where the IV goes in
- Nausea
- Sleepiness
- Irritation or inflammation at the infusion site
When to get medical help
- Tell your care team right away if you feel faint, very dizzy or lightheaded, since blood pressure can drop too low.
- Report a very slow heartbeat, chest pain or new shortness of breath.
- Report wheezing or trouble breathing, especially if you have asthma or similar lung problems.
- Report swelling, pain, blistering or skin damage at the IV site.
- Tell staff about signs of heart failure, such as new swelling or breathlessness.
Esmolol Warnings and Precautions
▾
- Low blood pressure can occur at any dose and may be severe
- Slow heartbeat, heart block and cardiac arrest have occurred
- It can worsen heart failure
- It can trigger bronchospasm in people with reactive airway disease
- It can raise potassium, especially with kidney problems
- It can mask low blood sugar or overactive thyroid signs
- Stopping beta blockers suddenly can worsen angina in people with coronary artery disease
- IV-site damage can occur, especially if the drug leaks out of the vein
Esmolol Interactions
▾
Esmolol can add to the effects of other heart and blood pressure drugs.
- Verapamil-type calcium-channel blockers given into a vein: fatal cardiac arrest has occurred
- Other blood pressure–lowering or heart-slowing drugs: can cause severe low blood pressure or slow heartbeat
- Digoxin: higher digoxin levels and a greater risk of slow heartbeat
- Succinylcholine and mivacurium: longer muscle relaxation
- Clonidine, guanfacine, moxonidine: rebound high blood pressure risk
- Epinephrine, norepinephrine, dopamine: avoid for fast heart rate
- Diabetes drugs: stronger blood sugar–lowering effect
Interactions listed in the FDA-approved label
From the Esmolol prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Digitalis glycosides: Concomitant administration of digoxin and esmolol leads to an approximate 10% to 20% increase of digoxin blood levels at some time points, and concomitant use increases the risk of bradycardia. Use only after careful individual assessment of the risks and expected benefits.
- Anticholinesterases: Esmolol prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.
- Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. If antihypertensive therapy needs to be interrupted or discontinued during concomitant beta blocker use, discontinue the beta blocker first, and the discontinuation should be gradual.
- Calcium channel antagonists (e.g., verapamil): In patients with depressed myocardial function, use with cardiodepressant calcium channel antagonists can lead to fatal cardiac arrests.
- Sympathomimetic drugs: Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of esmolol. Dose adjustment needed.
- Vasoconstrictive and positive inotropic agents (e.g., epinephrine, norepinephrine, dopamine): Risk of reducing cardiac contractility in presence of high systemic vascular resistance. Do not use esmolol to control tachycardia in patients receiving these drugs; avoid concomitant use.
Read the label’s full interactions text
7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injection’s effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below). Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: • Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. Digoxin does not affect esmolol hydrochloride in sodium chloride injection pharmacokinetics. Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use increases the risk of bradycardia. • Anticholinesterases: Esmolol hydrochloride in sodium chloride injection prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium. • Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before Taking Esmolol
▾
- Not for severe slow heart rate, heart block beyond first degree, sick sinus syndrome, decompensated heart failure, cardiogenic shock or pulmonary hypertension
- Not for people allergic to esmolol
- Pregnancy: use only if benefit outweighs risk; late pregnancy or labor use has caused a slow heart rate in babies
- Breastfeeding: unknown if it passes into milk
- Children: safety and effectiveness not established
- Older adults: start at the low end of dosing
- Kidney problems: monitor potassium; liver problems: no special precautions
Esmolol Overdose
▾
Too much esmolol can cause a very slow heartbeat, heart block, low blood pressure, heart failure, cardiac arrest, breathing problems, seizures and coma. The first step is to stop the infusion, and then the team treats the specific effects. Dilution errors have caused fatal overdoses, and patients survived when their circulation was supported until the drug wore off.
What Esmolol Does in the Body
▾
Esmolol lowers heart rate at rest and during exercise, and it slows electrical conduction in the heart. At typical doses it also lowers systolic blood pressure. Beta blockade wears off substantially 10 to 20 minutes after the infusion stops. In mildly asthmatic patients, esmolol did not significantly increase airway resistance.
How Your Body Processes Esmolol
▾
Esmolol is broken down quickly by esterases in red blood cells, not by the liver or kidneys. Its elimination half-life is about 9 minutes. Blood levels reach steady state within about 5 minutes with a loading dose, or about 30 minutes without one. Less than 2% leaves the body unchanged in the urine. Its main breakdown product is nearly inactive and is cleared by the kidneys.
How to Store Esmolol
▾
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F). Protect from freezing. Avoid excessive heat.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Esmolol: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Esmolol — the kind of thing our pharmacy team would talk through with you at the counter.
What is esmolol for?
▾
How will I get it?
▾
What side effects should I expect?
▾
How quickly does it wear off?
▾
Do I need to tell the team about other conditions or medicines?
▾
Is it safe in pregnancy?
▾
Is Esmolol available over the counter?
▾
When was Esmolol first available?
▾
Who makes Esmolol?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More About Esmolol on HelloPharmacist
Esmolol Forms and Strengths (How It Comes)
Esmolol is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Esmolol inactive ingredients by manufacturer.
Injection
How this form is used
- Brevibloc injection is used for short-term control of ventricular rate in atrial fibrillation, atrial flutter and supraventricular tachycardia, and for noncompensatory sinus tachycardia.
- Brevibloc injection is also used for short-term treatment of fast heart rate and high blood pressure during and after surgery.
- Brevibloc injection is given by continuous intravenous infusion, with or without a loading dose.
- Brevibloc dosing is adjusted in steps, checking heart rate or blood pressure at least every 4 minutes.
Esmolol on the U.S. Market: Products, Makers and Brands
How Esmolol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
14 companies list 36 Esmolol product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1982. Brand names on the directory include Brevibloc, Esmolol Hydrochloride in Water, esmolol hydrochloride in sodium chloride; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (4) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Esmolol Is Used (Medicaid Data)
A general measure of how commonly Esmolol is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Esmolol is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Esmolol prescribed? Of the 1,603 medications we measure, Esmolol ranks #986 by Medicaid prescriptions — more than 38% of them.
Utilization by Esmolol product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
10 ML esmolol hydrochloride 10 MG/ML Injection Most dispensed
Summed across the 5 of 28 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736546
250 ML esmolol hydrochloride 10 MG/ML Injection
Summed across the 2 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736541
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Esmolol, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 7 of 42 listed Esmolol NDCs with Medicaid activity.
Compare Esmolol Products
A representative set of FDA-listed product records for Esmolol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10 mg/mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Baxter Healthcare Company × 4 listings | NDA | View NDC → |
| 20 mg/mL | Intravenous | Baxter Healthcare Company × 3 listings | NDA | View NDC → |
| 10 mg/mL | Intravenous | Baxter Healthcare Corporation | NDA | View NDC → |
| 10 mg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Fresenius Kabi USA, LLC × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Gland Pharma Limited | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Henry Schein, Inc | NDA | View NDC → |
| 10 mg/mL | Intravenous | Henry Schein, Inc. | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | Henry Schein, Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 10 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 100 mg/10 mL | Intravenous | Medical Purchasing Solutions, LLC | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Mylan Institutional LLC × 2 listings | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Mylan Institutional LLC | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | ProPharma Distribution | ANDA | View NDC → |
| 100 mg/10 mL | Intravenous | Remedyrepack Inc. | ANDA | View NDC → |
| 10 mg/mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 20 mg/mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 10 mg/mL | Intravenous | WG Critical Care, LLC | NDA | View NDC → |
| 10 mg/mL | Intravenous | WG Critical Care, LLC | ANDA | View NDC → |
| 20 mg/mL | Intravenous | WG Critical Care, LLC | ANDA | View NDC → |
| 20 mg/mL | Intravenous | WG Critical Care, LLC | NDA | View NDC → |
Showing 36 of 36 products — FDA National Drug Code Directory. See every product, package size and price: browse all 36 Esmolol NDCs →
Esmolol Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Esmolol — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Esmolol in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Esmolol FDA Approval History
How Esmolol went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Esmolol Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Esmolol recalls since July 2021.
✅No Esmolol recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Oct 8, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 49737 2 dose forms · 4 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 377103In current FDA listingsClinical drug / strength (SCD) hydrochloride 250 MG/MLRxCUI 979436 -
Dose form (SCDF) Injection RxCUI 1736540In current FDA listingsClinical drug / strength (SCD) 10 ML esmolol hydrochloride 10 MG/MLRxCUI 1736546100 ML esmolol hydrochloride 20 MG/MLRxCUI 979432250 ML esmolol hydrochloride 10 MG/MLRxCUI 1736541
Look up RxCUI 49737 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Esmolol Supply and Shortage Status
Whether Esmolol is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Esmolol Brand Names
Esmolol is sold under 3 brand names in the FDA directory — Brevibloc, Esmolol Hydrochloride in Water, esmolol hydrochloride in sodium chloride. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who Makes Esmolol: Manufacturers and Labelers
14 companies list Esmolol products with the FDA. By number of product records, the largest are Baxter Healthcare Company, HF Acquisition Co LLC, DBA HealthFirst, WG Critical Care, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Esmolol Drug Class (RxNorm)
Esmolol belongs to the beta-Adrenergic Blocker class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for This Esmolol Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Baxter Healthcare Corporation is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →